Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432171 · ClinicalTrials.gov registry record · NA
Lacosamide in Preventing Seizures in Participants With Malignant Glioma
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT01432171: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT01432171 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01432171, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
This trial studies how well lacosamide works in preventing seizures in participants with malignant glioma. Anti-seizure drugs, such as lacosamide, may decrease abnormal electrical activity in the brain that plays a role in developing seizures.
Interventions
- OTHER Placebo
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-07-25 |
| Est. Completion | 2017-06-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01432171
The ClinicalTrials.gov registry entry for NCT01432171 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01432171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01432171 about?
NCT01432171 is a clinical study titled "Lacosamide in Preventing Seizures in Participants With Malignant Glioma". This trial studies how well lacosamide works in preventing seizures in participants with malignant glioma. Anti-seizure drugs, such as lacosamide, may decrease abnormal electrical activity in the brain that plays a role in developing seizures.
What is the current status of trial NCT01432171?
This trial is currently terminated. It is a NA study. The enrollment target is 37 participants. The study started on 2012-07-25. Estimated completion is 2017-06-20.
What interventions are being tested in trial NCT01432171?
The interventions under investigation include: Placebo (OTHER), Lacosamide (DRUG).
Who is sponsoring clinical trial NCT01432171?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.